MICHELLE EVANS: Open Payments
NPI 1760104178 · VIENNA, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$457 in 21 payments from 11 companies in 2025. Trend: 2023 $742 · 2024 $494 · 2025 $457
Food & beverage: $441Education: $16
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $115 |
| Lilly USA, LLC | 3 | $72 |
| Amgen Inc. | 2 | $47 |
| Dexcom, Inc. | 1 | $42 |
| Amneal Pharmaceuticals LLC | 2 | $42 |
| ABBVIE INC. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 |
| Novartis Pharmaceuticals Corporation | 1 | $22 |
| Insulet Corporation | 1 | $20 |
Products named: MOUNJARO, Wegovy, Ozempic, DEXCOM G7 GSS (161), UNITHROID, TEPEZZA, GLASSIA, JARDIANCE.
Industry payments across VA — which companies pay providers there.
